Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Semiparametric inference on the absolute risk reduction and the restricted mean survival difference.

Yang S.

Lifetime Data Anal. 2013 Apr;19(2):219-41. doi: 10.1007/s10985-013-9243-y. Epub 2013 Feb 8.

PMID:
23392737
2.

Estimation of the 2-sample hazard ratio function using a semiparametric model.

Yang S, Prentice RL.

Biostatistics. 2011 Apr;12(2):354-68. doi: 10.1093/biostatistics/kxq061. Epub 2010 Sep 21.

4.

Venous thrombosis and conjugated equine estrogen in women without a uterus.

Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR.

Arch Intern Med. 2006 Apr 10;166(7):772-80.

PMID:
16606815
5.

Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

Prentice RL, Langer RD, Stefanick ML, Howard BV, Pettinger M, Anderson GL, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2006 Apr 1;163(7):589-99. Epub 2006 Feb 16.

6.

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators.

Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20.

7.

Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials.

Perez MV, Wang PJ, Larson JC, Virnig BA, Cochrane B, Curb JD, Klein L, Manson JE, Martin LW, Robinson J, Wassertheil-Smoller S, Stefanick ML.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1108-16. doi: 10.1161/CIRCEP.112.972224. Epub 2012 Nov 20.

8.

Transdermal hormone therapy and the risk of stroke and venous thrombosis.

Speroff L.

Climacteric. 2010 Oct;13(5):429-32. doi: 10.3109/13697137.2010.507111.

PMID:
20670199
9.

Recent concerns surrounding HRT.

Armitage M, Nooney J, Evans S.

Clin Endocrinol (Oxf). 2003 Aug;59(2):145-55. Review.

PMID:
12864790
10.

A comparative review of the risks and benefits of hormone replacement therapy regimens.

Warren MP.

Am J Obstet Gynecol. 2004 Apr;190(4):1141-67. Review.

PMID:
15118656
11.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

12.

Estrogen plus progestin and risk of benign proliferative breast disease.

Rohan TE, Negassa A, Chlebowski RT, Lasser NL, McTiernan A, Schenken RS, Ginsberg M, Wassertheil-Smoller S, Page DL.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2337-43. doi: 10.1158/1055-9965.EPI-08-0380. Epub 2008 Aug 25.

13.
14.

Estrogen plus progestin and the risk of coronary heart disease.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators.

N Engl J Med. 2003 Aug 7;349(6):523-34.

15.

Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative.

Cirillo DJ, Wallace RB, Wu L, Yood RA.

Arthritis Rheum. 2006 Oct;54(10):3194-204.

16.

Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.

Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ.

Clin Trials. 2012 Oct;9(5):570-7. doi: 10.1177/1740774512455464. Epub 2012 Aug 22.

17.

Ambient particulate matter air pollution and venous thromboembolism in the Women's Health Initiative Hormone Therapy trials.

Shih RA, Griffin BA, Salkowski N, Jewell A, Eibner C, Bird CE, Liao D, Cushman M, Margolis HG, Eaton CB, Whitsel EA.

Environ Health Perspect. 2011 Mar;119(3):326-31. doi: 10.1289/ehp.1002256. Epub 2010 Oct 29.

18.

Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S.

Ann Intern Med. 2000 May 2;132(9):689-96.

PMID:
10787361
19.

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.

Simon JA, Hunninghake DB, Agarwal SK, Lin F, Cauley JA, Ireland CC, Pickar JH.

Ann Intern Med. 2001 Oct 2;135(7):493-501.

PMID:
11578152
20.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk